Melphalan Hydrochloride for Injection

ApprovedCompleted
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Jul 24, 2020 โ†’ Sep 18, 2021

About Melphalan Hydrochloride for Injection

Melphalan Hydrochloride for Injection is a approved stage product being developed by CASI Pharmaceuticals for Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT06425276. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT05438394Phase 1UNKNOWN
NCT06425276ApprovedCompleted